Insights for COVID-19 in 2023
Francisco Javier Martín‐Sánchez, Manuel Martínez‐Sellés, José Molero, Santiago Moreno Guillén, Fernando Rodríguez‐Artalejo, Julián Ruiz‐Galiana, Rafael Cantón, Pilar Ramos, Alejandra García‐Botella, Alberto García‐Lledó, Teresa Hernández‐Sampelayo, Javier Gómez‐Pavón, Juan González del Castillo, M.C. Martín Delgado, Emilio Bouza
Abstract
Predictions for a near end of the pandemic by the World Health Organization should be interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of classical mRNA vaccines (BT162b2 or mRNA-1273) is low and short-lived in preventing SARS-CoV-2 infection in its predominant variant (Omicron). However, its efficacy is high against severe symptomatic infection, hospitalization and death. The new vaccines being introduced are bivalent and active against the Omicron variants. Potential new vaccines to be introduced in the coming year include a vaccine based on a recombinant protein that emulates the receptor binding domain of the Spike protein under development by the Spanish company Hipra, as well as vaccines for nasal or oral administration. Available information suggests that vaccines against COVID-19 can be administered in association with influenza vaccination without particular complications. New drugs against COVID-19, both antiviral and anti-inflammatory, are under investigation, but this does not seem to be the case with monoclonal antibodies. The indication to use masks in some circumstances will be maintained next year in view of the accumulation of scientific data on their efficacy. Finally, the long COVID or Post-COVID syndrome may continue to affect a very high proportion of patients who have had the disease, requiring combined diagnostic and therapeutic resources.